12 Month Price Forecast For ELVN
Distance to ELVN Price Forecasts
ELVN Price Momentum
🤔 Considering Enliven Therapeutics (ELVN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 6:16 AM UTC
ELVN Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, ELVN has a consensus that is bullish. The median price target is $37.50, with forecasts ranging from $33.00 to $40.00. Currently, there are 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With ELVN currently trading at $22.05, the median price forecast suggests a 70.1% upside. The most optimistic forecast comes from Colleen Kusy at Baird, projecting a 81.4% upside, while at provides the most conservative target, suggesting a 49.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELVN Analyst Consensus
ELVN Price Target Range
Latest ELVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 15, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $40.00 |
| Oct 31, 2024 | Jones Trading | Soumit Roy | Buy | Initiates | $36.00 |
| Oct 1, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $37.00 |
| Sep 9, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Initiates | $37.00 |
| Jun 11, 2024 | Baird | Colleen Kusy | Outperform | Initiates | $32.00 |
| Apr 9, 2024 | Mizuho | Salim Syed | Buy | Initiates | $34.00 |
| Mar 29, 2023 | Jefferies | Eun Yang | Buy | Initiates | $27.00 |
| Mar 3, 2023 | TD Cowen | Outperform | Initiates | $0.00 |
Stocks Similar to Enliven Therapeutics, Inc. - Common Stock
The following stocks are similar to Enliven Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enliven Therapeutics, Inc. - Common Stock (ELVN) Financial Data
Enliven Therapeutics, Inc. - Common Stock has a market capitalization of $1.24B with a P/E ratio of -11.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -31.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Enliven Therapeutics, Inc. - Common Stock (ELVN) Company Overview
About Enliven Therapeutics, Inc. - Common Stock
Develops small molecule inhibitors for cancer treatment.
Enliven Therapeutics operates as a clinical-stage biopharmaceutical company, primarily focusing on the discovery and development of innovative small molecule inhibitors. The company generates revenue through the advancement of its drug candidates, which, upon successful clinical trials and regulatory approvals, can be commercialized for treating various types of cancer.
Enliven's lead product candidates, ELVN-001 and ELVN-002, are currently in Phase 1 clinical trials targeting chronic myeloid leukemia and solid tumors with HER2 alterations, respectively. The company is located in Boulder, Colorado, positioning it within a vibrant biotech ecosystem.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
46
CEO
Mr. Samuel S. Kintz M.B.A.
Country
United States
IPO Year
2023
Website
www.enliventherapeutics.comEnliven Therapeutics, Inc. - Common Stock (ELVN) Latest News & Analysis
Enliven's Early Data Stands Out From Peers
16 days agoEnliven Therapeutics' ELVN-001 shows a 44% major molecular response in CML patients after 12 weeks. The company has a $1.9bn market cap and a cash runway of 7–8 quarters for R&D.
Promising interim data for ELVN-001 could enhance Enliven's market position in CML treatment, potentially boosting its valuation and attracting investor interest amid a solid cash runway.
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
2 months agoEnliven Therapeutics reported a 44% cumulative MMR rate in its Phase 1 trial of ELVN-001 for CML, with good tolerability. The company has $292 million in cash, ensuring funding through late 2026.
Positive Phase 1 trial results for ELVN-001 indicate potential for effective CML treatment, while a strong cash position ensures funding for continued development, boosting investor confidence.
Enliven Therapeutics, Inc. (Nasdaq: ELVN) will participate in a fireside chat at the Jefferies London Healthcare Conference on November 19, 2024, at 9:30 a.m.
Enliven Therapeutics' participation in a major healthcare conference signals potential updates on their pipeline, impacting investor sentiment and stock performance.
Why Enliven is this analyst's top biotech stock pick
3 months agoSalim Syed of Mizuho Americas highlights Enliven Therapeutics (ELVN) as a top pharmaceutical pick due to promising drug developments.
Salim Syed's endorsement of Enliven Therapeutics (ELVN) highlights potential growth in the pharmaceutical sector, indicating investment opportunities based on promising drug developments.
Enliven Therapeutics, Inc. (ELVN) is highlighted as a potentially profitable investment, having passed a "Recent Price Strength" screening for fundamentally strong stocks.
Enliven Therapeutics shows strong momentum and fundamentals, indicating potential for profit. Stocks with recent price strength can attract investor interest and drive higher valuations.
Enliven Therapeutics reported positive Phase 1 trial results for ELVN-001 in CML, showing a 44% cumulative MMR rate by 24 weeks. The treatment was well-tolerated with no dose reductions.
Positive Phase 1 trial results for ELVN-001 in chronic myeloid leukemia indicate strong efficacy and safety, potentially enhancing Enliven Therapeutics' market position and attracting investor interest.
Frequently Asked Questions About ELVN Stock
What is Enliven Therapeutics, Inc. - Common Stock's (ELVN) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Enliven Therapeutics, Inc. - Common Stock (ELVN) has a median price target of $37.50. The highest price target is $40.00 and the lowest is $33.00.
Is ELVN stock a good investment in 2025?
According to current analyst ratings, ELVN has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $22.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ELVN stock?
Wall Street analysts predict ELVN stock could reach $37.50 in the next 12 months. This represents a 70.1% increase from the current price of $22.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enliven Therapeutics, Inc. - Common Stock's business model?
Enliven Therapeutics operates as a clinical-stage biopharmaceutical company, primarily focusing on the discovery and development of innovative small molecule inhibitors. The company generates revenue through the advancement of its drug candidates, which, upon successful clinical trials and regulatory approvals, can be commercialized for treating various types of cancer.
What is the highest forecasted price for ELVN Enliven Therapeutics, Inc. - Common Stock?
The highest price target for ELVN is $40.00 from Colleen Kusy at Baird, which represents a 81.4% increase from the current price of $22.05.
What is the lowest forecasted price for ELVN Enliven Therapeutics, Inc. - Common Stock?
The lowest price target for ELVN is $33.00 from at , which represents a 49.7% increase from the current price of $22.05.
What is the overall ELVN consensus from analysts for Enliven Therapeutics, Inc. - Common Stock?
The overall analyst consensus for ELVN is bullish. Out of 6 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $37.50.
How accurate are ELVN stock price projections?
Stock price projections, including those for Enliven Therapeutics, Inc. - Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
